Health of IVF Versus IVM Children (FM-BABIES)
Health of IVF Versus IVM Children (FM-BABIES)
The investigators conduct a follow up of our randomized controlled trial (RCT) to investigate
 the development of children born from In-vitro fertilization (IVF) and In-vitro maturation
 (IVM), in order to give strong evidence about the safety of IVM in women with high antral
 follicle count or especially polycystic ovary syndrome (PCOS).
Since the birth of the first baby born from in-vitro maturation (IVM) in 1991, this technique
 has been considered an alternative solution for treating infertility beside conventional
 controlled ovarian stimulation for in-vitro fertilization (IVF). Since then, there are
 already more than 5000 children born from IVM, and that number is on the trend of increasing.

 Regarding technique, immature oocytes (germinal vesicle - GV) were aspirated from secondary
 follicles sized from 2-10mm, under follicle-stimulating hormone (FSH) priming or no ovarian
 stimulation at all. Afterward, the maturation process was undertaken in an artificial medium,
 out of a living body. This technique, by reducing the usage of external hormones, is highly
 effective in minimizing the risk of ovarian hyperstimulation syndrome (OHSS) in women with
 high antral follicle count, especially polycystic ovarian syndrome, with a rate of OHSS
 recorded as low as 0 percent. Alongside that, the pregnancy rate, as well as the live birth
 rate of IVM, when proceeded well, is not lower than conventional IVF. Until now, there is
 only one randomized controlled trial comparing these two techniques directly.

 Due to differences in the process of culturing between IVM and IVF, primarily the maturation
 is undertaken in an artificial medium, the health of children born from IVM received many
 interests. Numerous studies have been conducted to compare the development of children born
 from IVM and IVF. Neonatal outcomes of children born from IVM and IVF are considerably
 comparable. And the development of children born from these two techniques is not
 significantly different. All the information, as mentioned above, was not from randomized
 controlled trials but retrospective or prospective cohort studies. Thus, we conduct a follow
 up of our RCT to investigate the development of children born from IVM and IVM, to give
 strong evidence about the safety of IVM in women with high antral follicle count or
 especially PCOS.
Inclusion Criteria:

 -  All live babies born following the In-vitro Maturation and In-vitro fertilization from
 our FM study.

 -  Parents agree to participate in the study.

 Exclusion Criteria:

 -  Babies died after perinatal period.